Navigation Links
AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO
Date:8/12/2008

QUEBEC CITY, Aug. 12 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), a global biopharmaceutical company focused on endocrinology and oncology, announced today the appointment of Prof. Jurgen Engel, Ph.D. as its new President and CEO, effective as of September 1, 2008. Prof. Engel is currently Executive Vice President and Chief Scientific Officer of AEterna Zentaris. He succeeds Juergen Ernst, who had been acting as Interim President and CEO since April 2008. Mr. Ernst, current Chairman at AEterna Zentaris, will become Executive Chairman as of September 1, 2008.

"As a seasoned executive for many years at AEterna Zentaris, Prof. Engel has gained a deep knowledge of the Company's activities at all levels. We feel that his extensive expertise in drug development and commercialization as well as in strategic partnerships, make him the ideal person to lead the Company," said Mr. Ernst.

Prof. Engel added, "I am thrilled with this new challenge and will continue to dedicate all efforts to the successful development of our deep pipeline, especially the ongoing pivotal Phase 3 program in benign prostatic hyperplasia with our lead compound, cetrorelix."

Prof. Engel has been Chief Executive Officer of Zentaris AG since the beginning of 2001. Before joining AEterna Zentaris in December 2002, he was in charge of all R&D activities at ASTA Medica AG where he supervised more than 700 scientists and clinical professionals.

Prof. Engel holds a doctorate degree in organic chemistry from the Technical University of Braunschweig and an academic degree in pharmaceutical science from the University of Regensburg where he is an adjunct full professor at its School of Pharmacy. He is also Honorary Professor at
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris to Announce Second Quarter 2008 Financial and Operating Results on August 12, 2008
2. AEterna Zentaris Sells Quebec City Building for $7.1 million
3. AEterna Zentaris to Present at Upcoming Rodman & Renshaw Global Healthcare Conference and AUA Annual Meeting
4. AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal
5. AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results
6. AEterna Zentaris to Announce First Quarter 2008 Financial and Operating Results and Hold Annual Shareholder Meeting on May 7, 2008
7. AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan
8. AEterna Zentaris Partner, Spectrum, Provides Update on Ozarelix in Benign Prostatic Hyperplasia
9. AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia
10. AEterna Zentaris Announces Changes to its Management Team
11. AEterna Zentaris and Paladin Labs Complete Sale and Purchase of Miltefosine Rights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... , August 26, 2015 Israel Proves Its ... wins 1 st place  Wayerz comes in 5 ... Israel by venture capital fund JVP, with Chinese ... US, China , Israel , ... .  Impressive achievement for the Israeli representatives in the ...
(Date:8/26/2015)... England , August 26, 2015 ... Ltd against Europlasma NV relating to P2i United ... have resolved their dispute in the United States ... liability on the part of either party. As a result ... Central District of California dismissed the ...
(Date:8/26/2015)... ... August 26, 2015 , ... PRC Clinical, a ... business relationships with local sponsors in southern California. The Clinical Trial Management Expert CRO ... processes and regulatory pathways., , Stem Cell Meeting on ...
(Date:8/25/2015)... 2015   WuXi PharmaTech (Cayman) Inc. (NYSE: ... platform company serving the pharmaceutical, biotechnology, and medical device ... Kong Exchange Stock Code: 0950), a research-based biopharmaceutical company ... 20 years of operations in China ... an agreement whereby WuXi,s Laboratory Testing Division (LTD) will ...
Breaking Biology Technology:Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6P2i Settles United States Litigation 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 2WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 3
... standardized clones , , Rebecca L. Mullinax ... Vilma Nioko ,Leonardo DeLeon SanDEe Soares ... Stevens Chris Hansen Brian Schilling ,Phenogenex , ... single dual- expression vector. These clones eliminate the time ...
... New BL21-Gold cells accelerate the protein expression ... Lisa Breister Alan,Greener ,Stratagene , Stratagene ... new BL21-Gold,series. Epicurian Coli ... EndA1 nuclease and offer 100-fold higher,transformation efficiencies than ...
... of interferon-stimulated signaling pathways , , Li ... Zheng ,Stratagene , Stratagenes family of PathDetect ... to better study the,activation of signal transduction pathways stimulated ... or - g . The pISRE-Luc,cis-reporter plasmid contains ...
Cached Biology Technology:Sequence-Validated and Expression-Tested Human cDNA in a Dual Expression,Vector 2Sequence-Validated and Expression-Tested Human cDNA in a Dual Expression,Vector 3Sequence-Validated and Expression-Tested Human cDNA in a Dual Expression,Vector 4Sequence-Validated and Expression-Tested Human cDNA in a Dual Expression,Vector 5Sequence-Validated and Expression-Tested Human cDNA in a Dual Expression,Vector 6High-efficiency Derivatives of the BL21 Series for Protein Expression 2High-efficiency Derivatives of the BL21 Series for Protein Expression 3New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction,Pathways 2New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction,Pathways 3New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction,Pathways 4New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction,Pathways 5New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction,Pathways 6
(Date:8/12/2015)... MINNETONKA, Minn. , Aug. 12, 2015   ... that supports the entire spectrum of clinical research, is ... ™ , the company,s comprehensive SaaS-based eClinical technology platform, ... growth during the first two quarters of 2015.   ... and second largest quarters measured by contract value sold ...
(Date:8/12/2015)... 12, 2015  New research unveiled at Black ... phones to steal users, fingerprints. Information released today ... fingerprint scanners on mobile devices, making the security ... biometrics on mobile devices, HYPR Corp. recently released ... authentication systems with strong cryptographic security. More information ...
(Date:8/11/2015)... August 11, 2015 Today, ZUK announced its ... as well as expected revenues in 2015 that relate to sales ... revenue guidance of approximately 2,200 MSEK for 2015. Jörgen ... prominent smartphone manufacturer in China ... selected FPC1 155 for Z1 ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2
... industry,s emissions are predicted to continue to grow in the ... avoid dangerous climate change if additional cuts are not made ... of Manchester study, the global shipping industry, despite being traditionally ... transport, releases increasing amounts of harmful emissions into the atmosphere ...
... Clemson University will lead a groundbreaking multistate, ... receiving a $1.2 million grant from the U.S. ... Agriculture. Results of the far-reaching project likely ... thousands of dollars a year in reduced pesticide ...
... report this month that MALAT1, a long non-coding RNA that ... critical step in the earliest stage of protein production. Their ... Nearly 5 percent of the human genome codes for proteins, ... the rest of the "non-coding" genome. Among the least studied ...
Cached Biology News:UK's shipping emissions 6 times higher than expected, says new report 2UK's shipping emissions 6 times higher than expected, says new report 3$1.2 million grant to support Clemson precision agriculture cotton research 2$1.2 million grant to support Clemson precision agriculture cotton research 3Cancer-associated long non-coding RNA regulates pre-mRNA splicing 2Cancer-associated long non-coding RNA regulates pre-mRNA splicing 3
Mouse monoclonal [3576] to Yellow Fever Virus ( Abpromise for all tested applications). Antigen: Tissue / cell preparation...
... Each Signet Level 2 Detection ... the avidin-biotin chemical bonding principle and ... to provide sensitivity, specificity and reliablility. ... immunostaining in both manual and automated ...
... Level 2 Detection System combines the ... bonding principle and Signets unique formulation ... specificity and reliablility. Signet reagents will ... manual and automated protocols. ,Signets ...
6X Loading Buffer is intended for gel electrophoresis of DNA fragments or PCR products....
Biology Products: